| Symbol | NVAX |
|---|---|
| Name | NOVAVAX INC |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biological Products, (No Diagnostic Substances) |
| Address | 21 FIRSTFIELD RD, GAITHERSBURG, MD None |
| Telephone | 240-268-2000 |
| Fax | — |
| — | |
| Website | https://www.novavax.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001000694 |
| Description | Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. Novavax develops product candidates geared toward all age demographics of the general population. Additional info from NASDAQ: |
New Form SCHEDULE 13G - NOVAVAX INC <b>Filed:</b> 2026-08-07 <b>AccNo:</b> 0000093751-26-000510 <b>Size:</b> 8 KB
Read moreNovavax Reports Second Quarter 2026 Financial Results and Operational Highlights
Read moreNovavax Reports Second Quarter 2026 Financial Results and Operational Highlights
Read moreNovavax to Report Second Quarter 2026 Financial Results on August 6, 2026
Read moreNovavax to Report Second Quarter 2026 Financial Results on August 6, 2026
Read moreDirector Rodgers Richard J 🟡 adjusted position in 35.5K shares (3 derivative) of NOVAVAX INC (NVAX) at $9.13 Transaction Date: Jun 18, 2026 | Filing ID: 076930
Read moreDirector King Rachel K. 🟡 adjusted position in 35.5K shares (3 derivative) of NOVAVAX INC (NVAX) at $9.13 Transaction Date: Jun 18, 2026 | Filing ID: 076928
Read moreDirector DOUGLAS RICHARD 🟡 adjusted position in 35.5K shares (3 derivative) of NOVAVAX INC (NVAX) at $9.13 Transaction Date: Jun 18, 2026 | Filing ID: 076927
Read moreDirector MCGLYNN MARGARET G 🟡 adjusted position in 35.5K shares (3 derivative) of NOVAVAX INC (NVAX) at $9.13 Transaction Date: Jun 18, 2026 | Filing ID: 076926
Read moreDirector MOTT DAVID M 🟡 adjusted position in 35.5K shares (3 derivative) of NOVAVAX INC (NVAX) at $9.13 Transaction Date: Jun 18, 2026 | Filing ID: 076925
Read more